Latest Antivirals Stories
- In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than 2 percent of patients experiencing virological failure NORTH CHICAGO, Ill., Dec.
-- ContraVir to develop CMX157 for multiple antiviral indications -- DURHAM, N.C. and EDISON, N.J., Dec. 18, 2014 /PRNewswire/ -- Chimerix, Inc.
EDISON, N.J., Dec. 16, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc.
EDISON, N.J., Dec. 11, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc.
EDISON, N.J., Dec. 9, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc.
- Major regulatory milestone achieved toward approval in the European Union NORTH CHICAGO, Ill., Nov.
- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) infection and human immunodeficiency virus (HIV) type 1 infection, TURQUOISE-I demonstrated sustained virologic response
- Results demonstrated high response rates in adult chronic hepatitis C genotype 4 patients without cirrhosis BOSTON, Nov.
--Expanded indication includes both treatment-naive and treatment-experienced adult patients with or without cirrhosis-- TITUSVILLE, N.J., Nov.
Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences EDISON,
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.